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D-Glucose-6-phosphate phosphohydrolase (G6Pase, E.C. 3.1.3.9) is a key regulatory enzyme in hepatic metabolisms.
The two metabolic pathways by which the liver can produce glucose are gluconeogenesis and glycogenolysis. G6Pase catalyzes the final step in both pathways. Excessive hepatic glucose output is a major cause of the fasting hyperglycemia that characterizes diabetes1). Since inhibition of G6Pase reduces hepatic glucose output via both pathways, it ought to lower blood glucose levels in diabetic subjects.
This hypothesis has been tested using inhibitors of G6Pase2). Glucose output was effectively lowered in rat livers perfused with 3-mercaptopicolinic acid, an inhibitor of G6Pase. However, this agent does not target G6Pase specifically, as it also inhibited phosphoenolpyruvate carboxykinase activity3). More recently, a series of synthetic derivatives of chlorogenic acid have been identified as selective inhibitors for G6Pase4), some of which have been shown to reduce blood glucose levels when administered intravenously to normal rats5) and to improve glucose tolerance in diabetic ob/ob mice6). However, for reasons of poor potency and bioavailability, none of these compounds has proven suitable for development as a treatment for diabetes in human patients.
Therefore, we set out to identify structurally novel inhibitors of rat hepatic endoplasmic reticulum G6Pase using microsomal membranes to screen microbial extracts. As a result, we found that the fungus Chloridium sp. CL48903 produces CJ-21,164 (I), which has potent activity against G6Pase. This paper deals with the fermentation, isolation, structural elucidation, and biological activity of I.
Results

Isolation
The fermentation broth (1 liter) was filtered after the addition of an equal volume of ethanol. The filtrate was concentrated to an aqueous solution and then extracted twice with 500ml of ethylacetate. The organic layer was dried over anhydrous Na2SO4 and concentrated to dryness. The oily residue was applied onto a column of Sephadex eluted with methanol.
The active fractions were concentrated and then subjected to a preparative HPLC on YMC Co. Ltd. which implies a conjugated aromatic system composed of a hydroxy benzoic acid moiety. The IR spectra showed absorption bands due to hydroxyl groups between 3500 and 3200cm-1, and carbonyl groups around 1700cm-1.
Structural Elucidation
The structure of I was elucidated through HMBC, phasesensitive ROESY, and FAB-MS analyses. The HMBC gave Table 2 . In the 13C NMR spectrum, the D-4 carbon was almost unobservable, probably because of its signalbroadening feature. However, through the HMBC, the existence of the D-4 carbon was extrapolated by the presence of cross peaks for D-4-Me and D-6-H. Among the 4-bond correlations, cross peaks for the two carbonyl groups (D-1, D-5) and D-7-Me were observed when we ran HMBC, focusing on the smaller coupling (4-5 Hz) in acetone-d6.
Carbons attached to hydroxyl groups (carbons A-1, B-3, C-3 and D-2) were specified by a high field shift of 13C NMR signals, which occurred when the hydroxyl groups were replaced by deuteroxyl groups. After the 13C NMR was thus elucidated as shown in Fig. 1 .
Biological Activities
The biological activities of I are summarized in Table 3 .
It dose-dependently inhibited G6Pase, with an IC50 value inhibited the rate of glucose output stimulated with 25nM glucagon by 81%. Hepatocytes incubated with I did not show significant cytotoxicity at these concentrations, suggesting that the reduction in glucose output was not a consequence of cytotoxicity.
Discussion
We have isolated a new G6Pase inhibitor, consisting of a tetramer of salicylic acid derivatives, and demonstrated its glucose-output inhibition in rat hepatocytes.
A number of salicylic acid related compounds have been found to exhibit a wide variety of biological activities, the most famous being aspirin [2-(acetyloxy) benzoic acid], which is widely used for its analgesic, antipyretic and anti-inflammatory properties. A group of salicylic acid derivatives having aliphatic side chains, such as anacardic acid8), was reported to possess antineoplastic, antibacterial, molluscicidal, and nematocidal activities. According to SAKEMI et al., thielavins9), trimers of salicylic acid derivatives, also showed activities against G6Pase. These were reported as prostagladin biosynthesis inhibitors10), while the dimer of salicylic acid derivatives and the anacardic acid related compounds did not inhibit the enzyme.
The trimer (thielavins) and tetrameter (I) of salicylic acid derivatives, unlike the dimers and monomers, may be conforming to the shape and/or size of the active site of the enzyme due to their 3-dimensional mobility, which would account for their G6Pase inhibitory activities.
Compound I was also functionally active in an isolated cell system, inhibiting the output of glucose from isolated rat hepatocytes. This suggests that this class of compounds may have therapeutic potential as anti-diabetic agents, since hepatic glucose output is elevated in diabetic patients1), furthermore, G6Pase inhibitors that reduce glucose output 1H and 13C references). Field gradient-HMBC and phasesensitive ROESY data were also obtained on a Bruker AVANCE 600 NMR Spectrometer in acetone-d6 and in methanol-d4.
Producing Microorganism
The producing strain, the fungus Chloridium sp.
CL48903, was obtained from the Sichuan Industrial Institute of Antibiotics, China.
Fermentation
Chloridium sp. CL48903 was maintained on an agar slant of Potato Dextrose Agar (Difco). The cell suspension was inoculated into a 500ml Erlenmeyer flask containing Sprague-Dawley rats (male, 200-220g) were fasted overnight, anaesthetized with ether, and had their livers excised, which were immediately washed with saline. The weight was recorded for each liver. The livers were chopped up and homogenized for 30 seconds (Polytron) in a homogenization buffer (250mM sucrose, 25mM HEPES, 2.5mM EDTA and 0.1mM phenylmethylsulfonyl fluoride, pH 7.4). The homogenate was centrifuged for 10 minutes at resulting microsomal pellet was resuspended in the homogenization buffer at a concentration of 1g (wet weight) of liver per ml and stored in aliquot parts at the glucose-6-phosphate-free assay buffer described below and was used for this screening.
G6Pase Activity
The activity of the G6Pase was measured based on the were dead prior to incubation, typically<10% of the total.
